Compare Organon & Co. Common Stock (OGN) vs Philip Morris International Inc. (PM) Price & Performance

Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.

OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.

Philip Morris International (PM) trades at $199.29, down 1.34% on the day, with strong earnings momentum after beating Q1 and Q2 2026 EPS estimates. The company shows robust fundamentals with 2025 revenue of $40.65B and net income margin of 25.56%, though valuation ratios appear elevated. Technical indicators show a bullish moving average trend but overbought RSI signals, with key support at $199. Recent news highlights expansion of smoke-free products like ZYN and IQOS, now representing over 40% of revenue.

PM's outlook remains positive with analyst consensus price target of $212.17 (6.5% upside) and 68% buy ratings. Growth is driven by smoke-free product adoption and international expansion, but risks include regulatory pressures, high debt levels, and premium valuation. The stock offers dividend income with recent $1.60 payout, supporting total return potential for investors comfortable with tobacco sector exposure.